after joining the study, you will undergo a series of baseline tests. these include measurements of vital signs such as blood pressure and heart rate, blood laboratory tests, an electrocardiogram (ecg) to check heart rhythm, and imaging scans to document the current size of the tumors.

the purpose of these assessments is to create a reference point that will be used to compare future changes during the study.

you will begin taking ro7782493, an oral film‑coated tablet. the tablet is taken by mouth according to the dosing schedule defined by the study protocol. the exact dose and how often you take the tablet (for example, once daily) will be explained by the study team and may be adjusted during the trial.

the medication is taken on an empty stomach unless the protocol specifies otherwise.

during the early part of the study, the dose of ro7782493 may be gradually increased to find the highest dose that can be tolerated safely. each increase will be made only after a review of safety data such as side effects and laboratory results.

you will continue to take the oral tablet at the new dose level for a defined period, typically several weeks, before the next evaluation.

once a safe dose of ro7782493 has been identified, you may receive panitumumab in combination with the oral tablet. panitumumab is given by iv infusion, which means the medication is delivered slowly into a vein through a small needle or catheter.

the infusion is administered in a clinic setting, usually over a period of 30 to 60 minutes, and the schedule (for example, once every two weeks) will be set by the study protocol.

throughout the treatment period you will attend regular clinic visits. at each visit you will have vital signs checked, blood drawn for laboratory tests, and an ecg performed to monitor heart function.

any side effects you experience will be recorded and graded according to a standard scale. the study team will use this information to decide whether the current dose can be continued, reduced, or stopped.

periodically (for example, every 6 to 8 weeks) imaging scans such as CT or MRI will be performed to assess changes in tumor size. these results help determine the effectiveness of the treatment.

the scans are compared with the baseline images to calculate measures such as objective response rate and duration of response.

treatment may be stopped if the disease progresses, if unacceptable side effects occur, or after a predefined maximum treatment duration.

after stopping the study drugs, you will continue to be followed for a period of time to monitor long‑term safety and disease status. follow‑up visits will include the same safety assessments and imaging as during treatment.